A Phase 1, Open-label, Non-randomized, Parallel Group, Single-dose Adaptive Study in Adults With Hepatic Impairment and Matched, Healthy Control Participants With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 Dec 2017 Planned End Date changed from 20 Nov 2017 to 18 May 2018.
- 05 Dec 2017 Planned primary completion date changed from 20 Nov 2017 to 18 May 2018.
- 01 Sep 2017 Status changed from not yet recruiting to recruiting.